Mild Cognitive ImpairmentABO-MEMONCT03581929
Efficacy of MEMORMAX in Subjects With MCI
A study testing Memormax in people with Mild Cognitive Impairment, run by Aboca Spa Societa' Agricola at 1 site in Italy.
Trial summary
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment. Open-label treatment, with all subjects receiving active treatment, for the next 6 months of study. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Mild Cognitive Impairment
- What is being tested?
- Memormax
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteItaly
- Study dates
- 20 Nov 2017to 19 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects with mild cognitive impairment, according to operational criteria for defining Mild Cognitive Impairment (MCI) (Albert et al, 2011): change in cognitive status, mild deficit in one or more cognitive domains, normal ability to perform activities in daily life or slight deficits not related to cognitive reasons, absence of dementia;
- MMSE≥24
- Good level of functional autonomy: ADL ≥ 5 / 6, IADL ≥ 4 / 8 for male subjects, ≥ 6/8 for female subjects, SPPB with score ≥ 9; Walk speed test in 6 meters ≥ 1 m / s;
- Written informed consent of the patient.
Who cannot join
- Subjects with malignant neoplasia in progress or diagnosed within 5 years;
- Subjects with active infections or autoimmune pathogenesis diseases (eg sclerosis, Chron, polymyalgia);
- Subjects diagnosed with neurodegenerative disease in pharmacological treatment (eg Parkinson's disease)
- Subjects with psychiatric conditions (eg psychosis, depression, schizophrenia)
- Subjects in pharmacological treatment for urinary incontinence
- Subjects with involuntary weight loss> 5 kg in the last twelve months;
Show all 15Show fewer
- Subjects with chronic renal failure ≥ stage III K-DOQI;
- Subjects with clinically significant liver disease (AST / SGOT, ALT / SGPT> 2 upper limits)
- Subjects with severe hearing, vision, speech or walking disabilities;
- Geriatric Depression Scale (Geriatric Depression Scale)> 4 out of 15 items;
- Consumption in the two months prior to the baseline assessment of supplements containing omega-3 fatty acids or foods containing fish oil, foods for special medical purposes (AFMS);
- Use in the month prior to baseline assessment of: atropine, scopolamine, tolterodine, iosciamin, biperidene, benzotropin, oxybutynin, antipsychotics, vitamins B, C and / or> at 200% of the suggested daily dose, highly energetic nutritional supplements and / or proteins, other products under experimentation;
- Alcohol abuse.
- Use of antibiotics in the two months preceding the baseline assessment;
- Regular use of probiotics, fiber supplements or laxative
Trial locations and contacts
1 site in 1 country.
Italy1 site
S.C. di Geriatria Ospedale S. Maria della Misericordia
Perugia, 06156
About this study
Official title: Randomized Controlled Trial to Evaluate the Efficacy of a Food Supplement, in Subjects With Mild Cognitive Impairment (MCI)
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment. Open-label treatment, with all subjects receiving active treatment, for the next 6 months of study.
Read the detailed description
Patients are enrolled in the department of Geriatria, Azienda Ospedaliera di Perugia. The group of this pilot project will include 50 subjects. All the volunteers who, in compliance with the inclusion and exclusion criteria, will be available for follow-up at twelve months and are able to give informed written consent guaranteeing adherence to the treatment will be enrolled in the study.
The study involves the collection of clinical data acquired as part of routine assessments for the type of subject included in this research project.
Visit 1 baseline: day 1 (time 0) Upon enrollment, all subjects, for whom informed consent will be obtained, will undergo a medical examination for an overall assessment of the state of health. In all subjects, a careful family, pathological and pharmacological anamnesis will be collected, data on the habits of life (nutrition, smoking, exercise) will be collected through a specific questionnaire and the main anthropometric parameters will be evaluated (weight, height,body mass index, waist / hip ratio) and the risk of development of cognitive impairment through the Brief Late-life Dementia Risk Index (Barnes et al., 2014).
The clinical examination will be completed by a standard assessment for the hematobiochemical and urinalysis examinations.
The results of the tests and of the tests carried out for the diagnosis of MCI, according to the clinical practice of the center, will be collected and used as baseline values, up to one month before entry into the study.
In addition, some physical performance tests will be performed (hand grip evaluation, timed up and go, SPPB, frailty index, bioimedenzometry (BIA)). The results of the following tests and examinations carried out for the diagnosis of MCI will be collected, in the month before entry into the study: ECG, physical performance test (through evaluation of ADL, IADL), cognitive performance test (FCSRT, MMSE, ACE -R, Digit Span forward, Digit Span back, Trail Making A and B, Babcock story, Rey test, Raven test, Token test, verbal fluency test, prose memory, copy of drawings, verbal reviews), tests for the presence of behavioral disorders (Neuropsychiatric Inventory scale, NPI) and mood (Geriatric Depression Scale, GDS), Cognitive Reserve Index (CRI) (Nucci et al., 2012) in order to verify if the cognitive reserve could somehow to explain the variability found.
At this visit the patient will be randomized to receive one of the following products daily for 6 months:
- Memormax, 2 vials / day B) Placebo, 2 vials / day. Each patient will receive a supply of 30 packs of 12 vials each of Memormax or Placebo. Finally, the material for stool collection will be delivered to the patients. Patients will then be instructed to not start treatment in the study before collecting the faecal sample. This sample must be returned to the center in the days immediately following the visit 1.
Visit 2 - time 6 months (± 5 days) After 6 months all subjects will be subjected to medical evaluation (functional and cognitive), venous blood sampling, urine test and ECG control. Any changes in concomitant therapies and any adverse events will be recorded. Unused and used vials will be collected for accounting and verification of treatment compliance. All the subjects in the study (n = 50) will receive for the next 6 months only Memormax, according to an open study design. Each patient will receive a supply of 30 packs of 12 vials each of Memormax.
Visit 3 - time 12 months (end of study / premature termination of the study) At twelve months, all subjects will be subjected to medical evaluation (functional and cognitive), peripheral venous blood sampling, urine test and ECG control. Any changes in concomitant therapies and any adverse events will be recorded. Unused and used vials will be collected for accounting and verification of treatment compliance. In the event of premature termination of the study by a patient, at any time after the start of treatment, all assessments scheduled for Visit 3 should be made, considering the visit itself as the conclusion of the study for that patient. It is specified that in the follow-up evaluations (6 and 12 months) the parallel versions of the instruments used at the baseline will be used to avoid learning effects.
- Conditions
- Mild Cognitive Impairment
- Being tested
- Memormax, Placebo
- Keywords
- Mild Cognitive Impairment, Dementia, Memormax, Food Supplement, Microbiota
- Medical subject headings
- Cognitive Dysfunction, Dementia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MemormaxDietary supplement
Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
PlaceboOther
Placebo comparator
| Study group | Role | What they receive |
|---|---|---|
| Memormax | Experimental | 2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360. Receives: Dietary Supplement: Memormax |
| Placebo | Placebo comparator | 2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Memormax efficacy on global cognitive performance (FCRST).
Effect of Memormax on global cognitive performance in patients with mild Mild Cognitive Impairment (MCI) after a 6 months treatment and compared to placebo (T0-T6), measured by the FREE AND CUED SELECTIVE REMINDING TEST (FCRST)
Measured: Day 0-180
Memormax efficacy on global cognitive performance (ACE-R).
Effect of Memormax on global cognitive performance in patients with mild Mild Cognitive Impairment (MCI) after a 6 months treatment and compared to placebo (T0-T6), measured by the ADDENBROOKE'S COGNITIVE EXAMINATION (ACE-R) tests.
Measured: Day 0-180
Effect of Memormax on global cognitive performance across the entire population (FCRST)
To evaluate the effect of Memormax on global cognitive performance across the entire population studied in a 6-month open-label extension phase (T6-T12), measured by the FCSRT
Measured: Day 181-360
Effect of Memormax on global cognitive performance across the entire population (ACE-R)
To evaluate the effect of Memormax on global cognitive performance across the entire population studied in a 6-month open-label extension phase (T6-T12), measured by the ACE-R
Measured: Day 181-360
Secondary outcomes (24)
variations of the main parameters of cognitive performance (MMSE)
Mini-Mental State Examination (MMSE) or Folstein test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. The MMSE test includes simple questions that are valuated using point subscales that are summed to have a maximunm of 30 points; the administration of the test takes between 5 and 10 minutes and cognitive functions of each patient are examinated as reported below; Orientation to time (0-5 points), Orientation to place (0-5 points), Registration (0-3 points), Attention and calculation (0-5 points), Recall (0-3 points), Language and Praxis (0-9 points).
If the score is greater than or equal to 24, patient has a normal cognition. Below 24 points, we can indicate a severe cognitive impairment (≤9 points), a moderate cognitive impairment (10-18 points) and a mild cognitive impairment (19-23 points). For these reasons, higher values represent a better outcome
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (Digit Span)
A digit-span task is used to measure working memory's number storage capacity. Participants see or hear a sequence of numerical digits and are tasked to recall the sequence correctly, with increasingly longer sequences being tested in each trial. The participant's span is the longest number of sequential digits that can accurately be remembered.measured with further tests that explore multiple cognitive functions compared to evaluations as primary objectives.
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (Trail Making)
The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.The test can provide information about visual search speed, scanning, speed of processing, mental flexibility, as well as executive functioning.
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (Babcock)
Babcock Story Recall Test (BSRT; Babcock \&. Levy, 1940) is a verbal memory measure in which participants are read a brief story and asked to provide a summary of the story.
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (Rey Test)
The Rey 15-Item test is a test designed by Rey (1964) to detect malingering.
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (Raven Test)
Raven's Progressive Matrices (often referred to simply as Raven's Matrices) or RPM is a nonverbal group test typically used in educational settings. It is usually a 60-item test used in measuring abstract reasoning and regarded as a non-verbal estimate of fluid intelligence
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (Token Test)
The original TT tested auditory verbal memory by having the subject point to tokens of 5 different colors, 2 shapes (circle, squares), and 2 sizes (small, large), in response to commands such as "touch the blue circle" (a one dimensional command, or 1-D, since the tokens differ only by color), or "touch the yellow square and the red circle" (a two dimensional command, or 2-D, since the tokens differ by color and/or shape), or "touch the small red circle and the large green square" (a three dimensional command, or 3-D, since the tokens differ by size, and/or color and/or shape).
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (Verbal Fluency)
Verbal fluency tests are a kind of psychological test in which participants have to produce as many words as possible from a category in a given time (usually 60 seconds)
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (NEPSY-II)
NEPSY-II is the only single measure that allows the clinician to create a tailored assessment across the following domains: Executive functioning, Attention Language, Memory and learning, Sensorimotor functioning, Social perception, Visuospatial processing. The results provide information relating to typical childhood disorders, which can lead to accurate diagnosis and intervention planning for success in school and at home
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (NPI)
Standard Neuropsychiatric Inventory-Questionnaire providing a brief assessment of neuropsychiatric symptomatology in routine clinical practice settings.
Standard Neuropsychiatric Inventory-Questionnaire, analyzes the Severity of the symptoms present within the last month on a 3-point scale: 1 (mild), 2 (moderate), 3 (severe). This questionnaire analyzes also the distress on a 5-points scale described below:
0 = Not distressing at all
- = Minimal
- = Mild
- = Moderate
- = Severe
- = Extreme or Very Severe
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (GDS)
The Geriatric Depression Scale (GDS) is a 30-item self-report assessment used to identify depression in the elderly. Patients have to answer, with YES (0 point) or NO (1 point), to the questions and the following general cutoff may be used to qualify the severity:
normal 0-9, mild depressives 10-19, severe depressives 20-30.
Measured: Day 0-180-360
variations of the main parameters of cognitive performance (Cognitive Reserve Index)
The cognitive Reserve Questionnaire (CRIq) is an instrument for measuring the cognitive reserve of an individual by means of the compilation of information relating to his or her entire adult life. This questionnaire analyzes the Education, Working Activity and Leisure Time with point subscales based on the years for each activity. The cognitive reserve outcome is valuated as below: low≤ 70, medium-low 70 : 84, medium 85 : 114, medium-high 115 : 130 , high ≥ 130
Measured: Day 0-180-360
variations of physical performance (BIA)
Bioelectrical impedance analysis (BIA)
Measured: Day 0-180-360
variations of physical performance (hand grip)
Hand grip test
Measured: Day 0-180-360
variations of physical performance ( timed up and go)
timed up and go test
Measured: Day 0-180-360
variations of physical performance (SPPB)
Short Physical Performance Battery (SPPB)
Measured: Day 0-180-360
variations of physical performance (Frailty index)
Frailty index was developed to assess for frailty risk in older adults using items collected in existing nursing datasets. This is a questionnaire composed by 10 items and represents an assessment instrument with scores ranging from 0-10. A score of 0 indicates no frailty; a score of 1-3 indicates frailty risk; and a score of 4 or greater indicates frailty
Measured: Day 0-180-360
variations of physical performance (ADL)
Activities of daily living (ADL)
Measured: Day 0-180-360
variations of physical performance (IADL)
Instrumental Activities of Daily Living (IADL)
Measured: Day 0-180-360
variations of modification of biochemical parameters of inflammation.
Measuring circulating levels of inflammation cytokines: EGF, Eotaxin, G-CSF, GM-CSF, IFNα2, IFNγ, IL-10, IL-12P40, IL-12P70, IL-13, IL-15, IL-17A, IL-1RA, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, TNFα, TNFβ, VEGF, FGF-2, TGF-α, FIT-3L, Fractalkine, GRO, MCP-3, MDC, PDGF-AA, PDGF-BB, sCD40L, and IL-9.
Measured: Day 0-180-360
variations of modification of oxidative stress conditions parameters.
Measuring circulating levels of E Vitamins, Superoxide dismutase (SOD), catalase, GPx.
Measured: Day 0-180-360
variations of changes in the microbiota (bacteria subpopulations)
to evaluate the potential variations of changes in bacteria populations in the microbiota after 6 and after 12 months of treatment compared to baseline and compared to placebo.
Measured: Day 0-180-360
variations of changes in the microbiota (SCFA)
to evaluate the potential variations of changes in short chain fatty acids levels in the microbiota after 6 and after 12 months of treatment compared to baseline and compared to placebo.
Measured: Day 0-180-360
Safety and Tolerability (Adverse Events)
Number of Adverse events and serious adverse events that will be recorded throughout the duration of the study.
Measured: Day 0 to Day 360
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2018
- Study start20 Nov 2017
- Primary completion19 Dec 2019
- Study completion19 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aboca Spa Societa' Agricola
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Latis S.r.l.
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03581929
- Sponsor's protocol ID
- MEMORMAX
- Acronym
- ABO-MEMO
- Status last verified
- Jul 2020
- First submitted
- 15 May 2018
- Last updated
- 29 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Trial to Evaluate the Efficacy of a Food Supplement, in Subjects With Mild Cognitive Impairment (MCI)
- ClinicalTrials.gov ID
- NCT03581929
- Acronym / sponsor ID
- ABO-MEMO / MEMORMAX
- Conditions
- Mild Cognitive Impairment
- Keywords
- Mild Cognitive Impairment, Dementia, Memormax, Food Supplement, Microbiota
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Aboca Spa Societa' AgricolaIndustry (pharma, biotech, devices)
- Collaborators
- Latis S.r.l.
- Study start
- 20 Nov 2017 (actual)
- Primary completion
- 19 Dec 2019 (actual)
- Study completion
- 19 Dec 2019 (actual)
- First posted
- 10 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment. Open-label treatment, with all subjects receiving active treatment, for the next 6 months of study.
Detailed description
Patients are enrolled in the department of Geriatria, Azienda Ospedaliera di Perugia. The group of this pilot project will include 50 subjects. All the volunteers who, in compliance with the inclusion and exclusion criteria, will be available for follow-up at twelve months and are able to give informed written consent guaranteeing adherence to the treatment will be enrolled in the study.
The study involves the collection of clinical data acquired as part of routine assessments for the type of subject included in this research project.
Visit 1 baseline: day 1 (time 0) Upon enrollment, all subjects, for whom informed consent will be obtained, will undergo a medical examination for an overall assessment of the state of health. In all subjects, a careful family, pathological and pharmacological anamnesis will be collected, data on the habits of life (nutrition, smoking, exercise) will be collected through a specific questionnaire and the main anthropometric parameters will be evaluated (weight, height,body mass index, waist / hip ratio) and the risk of development of cognitive impairment through the Brief Late-life Dementia Risk Index (Barnes et al., 2014).
The clinical examination will be completed by a standard assessment for the hematobiochemical and urinalysis examinations.
The results of the tests and of the tests carried out for the diagnosis of MCI, according to the clinical practice of the center, will be collected and used as baseline values, up to one month before entry into the study.
In addition, some physical performance tests will be performed (hand grip evaluation, timed up and go, SPPB, frailty index, bioimedenzometry (BIA)). The results of the following tests and examinations carried out for the diagnosis of MCI will be collected, in the month before entry into the study: ECG, physical performance test (through evaluation of ADL, IADL), cognitive performance test (FCSRT, MMSE, ACE -R, Digit Span forward, Digit Span back, Trail Making A and B, Babcock story, Rey test, Raven test, Token test, verbal fluency test, prose memory, copy of drawings, verbal reviews), tests for the presence of behavioral disorders (Neuropsychiatric Inventory scale, NPI) and mood (Geriatric Depression Scale, GDS), Cognitive Reserve Index (CRI) (Nucci et al., 2012) in order to verify if the cognitive reserve could somehow to explain the variability found.
At this visit the patient will be randomized to receive one of the following products daily for 6 months:
- Memormax, 2 vials / day B) Placebo, 2 vials / day. Each patient will receive a supply of 30 packs of 12 vials each of Memormax or Placebo. Finally, the material for stool collection will be delivered to the patients. Patients will then be instructed to not start treatment in the study before collecting the faecal sample. This sample must be returned to the center in the days immediately following the visit 1.
Visit 2 - time 6 months (± 5 days) After 6 months all subjects will be subjected to medical evaluation (functional and cognitive), venous blood sampling, urine test and ECG control. Any changes in concomitant therapies and any adverse events will be recorded. Unused and used vials will be collected for accounting and verification of treatment compliance. All the subjects in the study (n = 50) will receive for the next 6 months only Memormax, according to an open study design. Each patient will receive a supply of 30 packs of 12 vials each of Memormax.
Visit 3 - time 12 months (end of study / premature termination of the study) At twelve months, all subjects will be subjected to medical evaluation (functional and cognitive), peripheral venous blood sampling, urine test and ECG control. Any changes in concomitant therapies and any adverse events will be recorded. Unused and used vials will be collected for accounting and verification of treatment compliance. In the event of premature termination of the study by a patient, at any time after the start of treatment, all assessments scheduled for Visit 3 should be made, considering the visit itself as the conclusion of the study for that patient. It is specified that in the follow-up evaluations (6 and 12 months) the parallel versions of the instruments used at the baseline will be used to avoid learning effects.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Memormax | Experimental | Dietary Supplement: Memormax2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360. |
| Placebo | Placebo comparator | Other: Placebo2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360. |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Subjects with mild cognitive impairment, according to operational criteria for defining Mild Cognitive Impairment (MCI) (Albert et al, 2011): change in cognitive status, mild deficit in one or more cognitive domains, normal ability to perform activities in daily life or slight deficits not related to cognitive reasons, absence of dementia;
- MMSE≥24
- Good level of functional autonomy: ADL ≥ 5 / 6, IADL ≥ 4 / 8 for male subjects, ≥ 6/8 for female subjects, SPPB with score ≥ 9; Walk speed test in 6 meters ≥ 1 m / s;
- Written informed consent of the patient.
Key exclusion criteria (15 listed)
- Subjects with malignant neoplasia in progress or diagnosed within 5 years;
- Subjects with active infections or autoimmune pathogenesis diseases (eg sclerosis, Chron, polymyalgia);
- Subjects diagnosed with neurodegenerative disease in pharmacological treatment (eg Parkinson's disease)
- Subjects with psychiatric conditions (eg psychosis, depression, schizophrenia)
- Subjects in pharmacological treatment for urinary incontinence
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MemormaxMemormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice. | Dietary supplement | Memormax |
| PlaceboPlacebo comparator | Other | Placebo |
Primary outcome
Memormax efficacy on global cognitive performance (FCRST).
Time frame: Day 0-180
Effect of Memormax on global cognitive performance in patients with mild Mild Cognitive Impairment (MCI) after a 6 months treatment and compared to placebo (T0-T6), measured by the FREE AND CUED SELECTIVE REMINDING TEST (FCRST)
Memormax efficacy on global cognitive performance (ACE-R).
Time frame: Day 0-180
Effect of Memormax on global cognitive performance in patients with mild Mild Cognitive Impairment (MCI) after a 6 months treatment and compared to placebo (T0-T6), measured by the ADDENBROOKE'S COGNITIVE EXAMINATION (ACE-R) tests.
Effect of Memormax on global cognitive performance across the entire population (FCRST)
Time frame: Day 181-360
To evaluate the effect of Memormax on global cognitive performance across the entire population studied in a 6-month open-label extension phase (T6-T12), measured by the FCSRT
Effect of Memormax on global cognitive performance across the entire population (ACE-R)
Time frame: Day 181-360
To evaluate the effect of Memormax on global cognitive performance across the entire population studied in a 6-month open-label extension phase (T6-T12), measured by the ACE-R
24 secondary outcomes
variations of the main parameters of cognitive performance (MMSE)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (Digit Span)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (Trail Making)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (Babcock)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (Rey Test)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (Raven Test)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (Token Test)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (Verbal Fluency)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (NEPSY-II)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (NPI)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (GDS)
Time frame: Day 0-180-360
variations of the main parameters of cognitive performance (Cognitive Reserve Index)
Time frame: Day 0-180-360
variations of physical performance (BIA)
Time frame: Day 0-180-360
variations of physical performance (hand grip)
Time frame: Day 0-180-360
variations of physical performance ( timed up and go)
Time frame: Day 0-180-360
variations of physical performance (SPPB)
Time frame: Day 0-180-360
variations of physical performance (Frailty index)
Time frame: Day 0-180-360
variations of physical performance (ADL)
Time frame: Day 0-180-360
variations of physical performance (IADL)
Time frame: Day 0-180-360
variations of modification of biochemical parameters of inflammation.
Time frame: Day 0-180-360
variations of modification of oxidative stress conditions parameters.
Time frame: Day 0-180-360
variations of changes in the microbiota (bacteria subpopulations)
Time frame: Day 0-180-360
variations of changes in the microbiota (SCFA)
Time frame: Day 0-180-360
Safety and Tolerability (Adverse Events)
Time frame: Day 0 to Day 360
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2020.
- Individual participant dataSharing planned: No
Related trials for Mild Cognitive Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Recruiting
Telehealth-Adapted Compensatory Training and Intervention for Cognition
MCI, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Memormax in people with Mild Cognitive Impairment, run by Aboca Spa Societa' Agricola at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Memormax efficacy on global cognitive performance (FCRST). (time frame: Day 0-180). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2020.